Indoleamine 2,3-dioxygenase 1 inhibitors: Molecular pharmacology, structural biology and medicinal chemistry with therapeutic perspectives for Huntington's disease.
- DOI
- 10.1016/j.bbapap.2026.141177
- Published
- 2026 Sep 18
- Container
- Biochimica et biophysica acta. Proteins and proteomics
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.bbapap.2026.141177,
title = {Indoleamine 2,3-dioxygenase 1 inhibitors: Molecular pharmacology, structural biology and medicinal chemistry with therapeutic perspectives for Huntington's disease.},
author = {Malakar V and Malakar CC and Mali PC and Poddar NK},
year = {2026},
journal = {Biochimica et biophysica acta. Proteins and proteomics},
doi = {10.1016/j.bbapap.2026.141177},
url = {https://doi.org/10.1016/j.bbapap.2026.141177}
}RIS
TY - JOUR TI - Indoleamine 2,3-dioxygenase 1 inhibitors: Molecular pharmacology, structural biology and medicinal chemistry with therapeutic perspectives for Huntington's disease. AU - Malakar V AU - Malakar CC AU - Mali PC AU - Poddar NK PY - 2026 JO - Biochimica et biophysica acta. Proteins and proteomics DO - 10.1016/j.bbapap.2026.141177 UR - https://doi.org/10.1016/j.bbapap.2026.141177 ER -
APA
V, M., CC, M., PC, M., & NK, P. (2026). Indoleamine 2,3-dioxygenase 1 inhibitors: Molecular pharmacology, structural biology and medicinal chemistry with therapeutic perspectives for Huntington's disease.. Biochimica et biophysica acta. Proteins and proteomics. https://doi.org/10.1016/j.bbapap.2026.141177
Source records
- pubmed · retrieved 2026-09-25T20:22:39.073Z